Enter your terms above and click the 'Search' button.

Showing articles 0 to 13 of 13 Filter Applied: multiple sclerosis,relapsing (Click to remove) Natalizumab-Associated PML Neurol 88:1197-1205, Schwab, N.,et al, 2017 Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012 Alemtuzumab for Multiples Sclerosis: Who and When to treat? Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012 Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010 Relapse Management in Multiple Sclerosis The Neurologist 15:1-5, Thrower,B.W., 2009 Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis NEJM 354:911-923,965, Rudick,R.A.,et al, 2006 A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis NEJM 354:899-910,965, Polman,C.H.,et al, 2006 Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses Neurol 50:398-402, Achiron,A.,et al, 1998 Intravenous Immunoglobulin G Reduces MRI Activity in Relapsing Multiple Sclerosis Neurol 50:1273-1281, Sorensen,P.S.,et al, 1998 Randomised Placebo-Controlled Trial of Monthly IVIg Therapy in Relapsing-Remitting MS Lancet 349:589-593, 5861997., Fazekas,F.,et al, 1997 Management of Multiple Sclerosis NEJM 337:1604-1611, Rudick,R.A.,et al, 1997 Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis Arch Neurol 49:1233-1236, Achiron,A.,et al, 1992 Severely Threatening Events and Marked Life Difficulties Preceding Onset or Exacerbation of MS JNNP 52:8-13, Grant,I.,et al, 1989 Showing articles 0 to 13 of 13